Grippol Plus — Competitive Intelligence Brief

Grippol Plus (Grippol Plus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated influenza vaccine Immunology / Infectious Disease Biologic

Target snapshot

Grippol Plus (Grippol Plus) — NPO Petrovax. Grippol Plus is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Grippol Plus TARGET	Grippol Plus	NPO Petrovax	phase 3	Inactivated influenza vaccine
Fluzone® (IM)	Fluzone® (IM)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	inactivated influenza vaccine
inactivated split-virus influenza vaccine	inactivated split-virus influenza vaccine	The Cleveland Clinic	marketed	inactivated influenza vaccine
Pandemic influenza A/H1N1 vaccine	Pandemic influenza A/H1N1 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
Prepandrix™	Prepandrix™	GlaxoSmithKline	marketed	Inactivated influenza vaccine	H5N1 influenza virus surface antigens (hemagglutinin and neuraminidase)
Fluarix Tetra Vaccine	Fluarix Tetra Vaccine	GlaxoSmithKline	marketed	Inactivated influenza vaccine
Flublok™ Quadrivalent by Sanofi, Inc.	Flublok™ Quadrivalent by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Recombinant inactivated influenza vaccine	Influenza hemagglutinin (HA) protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Seqirus · 5 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
4. Green Cross Corporation · 4 drugs in this class
5. Novartis · 2 drugs in this class
6. SK Chemicals Co., Ltd. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Hospital Israelita Albert Einstein · 2 drugs in this class
9. McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
10. Il-Yang Pharm. Co., Ltd. · 2 drugs in this class